Zacks Research Has Bullish Estimate for Imunon Q3 Earnings

Imunon, Inc. (NASDAQ:IMNN) – Stock analysts at Zacks Research upped their Q3 2026 earnings per share estimates for shares of Imunon in a research note issued on Wednesday, August 19th. Zacks Research analyst D. Bautz now forecasts that the company will post earnings of ($0.56) per share for the quarter, up from their previous estimate of ($0.87). The consensus estimate for Imunon’s current full-year earnings is ($2.63) per share. Zacks Research also issued estimates for Imunon’s Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($2.47) EPS, FY2027 earnings at ($2.01) EPS and FY2028 earnings at ($1.85) EPS.

Imunon (NASDAQ:IMNN) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.33.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Imunon in a research note on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Imunon currently has a consensus rating of “Hold” and an average target price of $10.00.

Imunon Stock Performance

Imunon stock opened at $1.58 on Friday. Imunon has a fifty-two week low of $1.47 and a fifty-two week high of $6.96. The firm’s 50 day simple moving average is $1.75 and its 200-day simple moving average is $2.46. The company has a debt-to-equity ratio of 2.86, a current ratio of 1.82 and a quick ratio of 1.82. The company has a market cap of $8.86 million, a P/E ratio of -0.41 and a beta of 1.97.

Institutional Investors Weigh In On Imunon

An institutional investor recently bought a new position in Imunon stock. Armistice Capital LLC bought a new stake in Imunon, Inc. (NASDAQ:IMNN) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 266,886 shares of the company’s stock, valued at approximately $1,017,000. Armistice Capital LLC owned 8.69% of Imunon at the end of the most recent reporting period. 4.47% of the stock is owned by hedge funds and other institutional investors.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.